---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-013652"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T07:33:48.824155+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioLife Solutions Q1 revenue up 4% to $37.7M; net loss widens, explores sale of freezer lines

## Summary
- Revenue $37.7M (+4% YoY); ex-COVID growth 16%; biopreservation media revenue +28%.
- GAAP net loss $13.7M (-$0.32/share) vs $7.4M loss in Q1 2022; adjusted EBITDA -$1.9M.
- Adjusted gross margin improved to 37% from 32% in Q4 2022; GAAP gross margin 35%.
- Exploring strategic alternatives for ULT cryogenic freezer businesses, including potential divestitures.
- Affirmed FY2023 revenue guidance $188-$202M (16-25% YoY growth); Q4'24 aspirational targets reaffirmed.

## SEC filing metadata
- accession: 0001437749-23-013652
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000143774923013652/0001437749-23-013652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000143774923013652/bioli20230510_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-013652
- JSON: https://secwatch.observer/filing/0001437749-23-013652.json
- Plain text: https://secwatch.observer/filing/0001437749-23-013652.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.